<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826045</url>
  </required_header>
  <id_info>
    <org_study_id>UMT2012-BL-PGA-01</org_study_id>
    <secondary_id>12335</secondary_id>
    <nct_id>NCT01826045</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia</brief_title>
  <acronym>PGA</acronym>
  <official_title>A Multi-center, Randomized, Double Blind, Placebo Control, Parallel Design, Phase 2a Trial to Evaluate the Efficacy and Safety of PGA (Poly-gamma Glutamic Acid) for the Fertile Women With Cervical Intraepithelial Neoplasia 1 (CIN1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLeaders Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLeaders Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and the safety of PGA(Poly-gamma
      Glutamic Acid) for the the fertile women with Cervical Intraepithelial Neoplasia (CIN1).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to compare the regression rate of Cervical Intraepithelial Neoplasia (CIN1)
      between the treatment group and the control group.

      The treatment group will be administered with PGA (Poly-gamma Glutamic Acid) for 4 weeks
      followed by 8 weeks observation.

      The control group will be observed for 12 weeks without any comparator.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression rate</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Regression rate will be assessed at the time of screening and 12 weeks. Regression means the change from the stage of CIN1 to normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reid Colposcopic Index</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Reid Colposcopic Index will be assessed at the time of screening and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pap smear test</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Result of Pap smear test will be assessed at the time of screening and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV (Human Papilloma Virus) DNA Test</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Result of HPV (Human Papilloma Virus) DNA Test will be assessed at the time of screening and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPV (Human Papilloma Virus) Hybrid CaptureII Test</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Result of HPV (Human Papilloma Virus) Hybrid CaptureII Test will be assessed at the time of screening and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK (Natural Killer) Cell Activity</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Result of NK (Natural Killer) Cell Activity will be assessed at the time of baseline (0day), 4 weeks, 8 weeks and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral Blood Mononuclear Cells (PBMCs)Test</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Result of Peripheral Blood Mononuclear Cells (PBMCs) Test will be assessed at the time of baseline (0day), 4 weeks, 8 weeks and 12 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Adverse events will be monitored for 12 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Vital signs will be monitored for 12 weeks.</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory Tests</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Result of laboratory tests will be assessed at screening.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>Poly-gamma Glutamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poly-gamma Glutamic Acid</intervention_name>
    <arm_group_label>Poly-gamma Glutamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fertile women between age of 20 and 49

          -  Patients with cervical intraepithelial neoplasia 1(CIN1)

          -  HPV(Human Papilloma Virus) positive(+)

          -  White Blood Cell Count(WBC) over 4thous/ul, Hemoglobin above over 9.0g/dL Platelet
             over 150thous/uL and ANC(Absolute Neutrophil Count) over 1,500 10^6/L

          -  AST(Aspartate Aminotransferase) no less than 4 times higher than normal ALT(Alanine
             Aminotransferase) no less than 4 times higher than normal

          -  Normal for EKG(Electrocardiography) and no active disease detected trough chest X-ray

          -  Be informed of the nature of the study and will give written informed consent

        Exclusion Criteria:

          -  Malignant tumor in any organ other than cervical intraepithelial neoplasia

          -  Active liver disease, immune disorder and severe renal failure

          -  Leukemia, collagenosis, sclerosis, autoimmune disease, clinically significant allergic
             disease(mild allergic symptom not required medicine excluded)

          -  Diagnosed diabetes

          -  Taking any of followings affecting immunological reaction within 7 days
             (Glucocorticoid, vitamins, health food and oriental medicine etc)

          -  Pregnancy and breastfeeding

          -  Registered in other clinical trials

          -  Patients whom the investigator considers inappropriate to participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Kwan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tae Jin Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kwandong University College of Medicine Cheil Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Sup Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University, Korea Seoul St Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chi-Heum Cho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Dongsan Medical Center of Keimyung University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seok Ju Seong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongsoo Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MizMedi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Dongsan Medical Center of Keimyung Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwandong University College of Medicine Cheil Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Gangnam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-913</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University, Korea Seoul St Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MiZMedi Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>157-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of Cervical Intraepithelial Neoplasia(CIN1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

